JPWO2023192977A5 - - Google Patents

Info

Publication number
JPWO2023192977A5
JPWO2023192977A5 JP2024558028A JP2024558028A JPWO2023192977A5 JP WO2023192977 A5 JPWO2023192977 A5 JP WO2023192977A5 JP 2024558028 A JP2024558028 A JP 2024558028A JP 2024558028 A JP2024558028 A JP 2024558028A JP WO2023192977 A5 JPWO2023192977 A5 JP WO2023192977A5
Authority
JP
Japan
Prior art keywords
nucleotide
phosphate
seq
salt
dsrna agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513757A5 (https=
JP2025513757A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065196 external-priority patent/WO2023192977A2/en
Publication of JP2025513757A publication Critical patent/JP2025513757A/ja
Publication of JP2025513757A5 publication Critical patent/JP2025513757A5/ja
Publication of JPWO2023192977A5 publication Critical patent/JPWO2023192977A5/ja
Pending legal-status Critical Current

Links

JP2024558028A 2022-04-01 2023-03-31 ＳＮＣＡ関連疾患を処置するためのＳＮＣＡ標的化ｓｉＲＮＡ組成物 Pending JP2025513757A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263326770P 2022-04-01 2022-04-01
US63/326,770 2022-04-01
US202263326813P 2022-04-02 2022-04-02
US63/326,813 2022-04-02
PCT/US2023/065196 WO2023192977A2 (en) 2022-04-01 2023-03-31 Snca-targeting sirna compositions for treating snca-associated disease

Publications (3)

Publication Number Publication Date
JP2025513757A JP2025513757A (ja) 2025-04-30
JP2025513757A5 JP2025513757A5 (https=) 2026-04-03
JPWO2023192977A5 true JPWO2023192977A5 (https=) 2026-04-03

Family

ID=88203639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024558028A Pending JP2025513757A (ja) 2022-04-01 2023-03-31 ＳＮＣＡ関連疾患を処置するためのＳＮＣＡ標的化ｓｉＲＮＡ組成物

Country Status (13)

Country Link
US (2) US20250059541A1 (https=)
EP (1) EP4504938A2 (https=)
JP (1) JP2025513757A (https=)
KR (1) KR20240166577A (https=)
CN (1) CN119156448A (https=)
AU (1) AU2023241905A1 (https=)
CA (1) CA3254960A1 (https=)
CL (1) CL2024002960A1 (https=)
CO (1) CO2024012499A2 (https=)
IL (1) IL315594A (https=)
MX (1) MX2024011539A (https=)
TW (1) TW202407100A (https=)
WO (1) WO2023192977A2 (https=)

Similar Documents

Publication Publication Date Title
JP3926840B2 (ja) 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用
CN110846316B (zh) 在基因沉默中具有降低的脱靶效应的una寡聚物
JP2020533334A5 (https=)
JPWO2020132227A5 (https=)
JP2019525918A5 (https=)
JP2007523943A (ja) 医薬組成物
US10933081B2 (en) Myostatin iRNA compositions and methods of use thereof
US9481887B2 (en) DNA aptamers for promoting remyelination
AU2022334739A1 (en) Compounds and methods for modulating scn1a expression
EP4396351A1 (en) Compounds and methods for reducing dmpk expression
WO2024008114A1 (zh) 用于抑制补体因子B表达的siRNA、其缀合物和药物组合物及其用途
JP2024544532A (ja) Ｈｂｖの処置のための医薬組合せ
JP2000514095A (ja) 生物学的利用能を向上するためのオリゴヌクレオチド
JPWO2023192977A5 (https=)
AU2024220263A1 (en) Allele-selective compounds and methods for modulating huntingtin expression
JPWO2021195467A5 (https=)
RU2024129253A (ru) КОМПОЗИЦИИ SNCA-НАПРАВЛЕННЫХ миРНК ДЛЯ ЛЕЧЕНИЯ SNCA-АССОЦИИРОВАННОГО ЗАБОЛЕВАНИЯ
JPWO2021222065A5 (https=)
JP2023545041A (ja) Ｄｍｄ患者におけるエクソン５１スキッピングによるジストロフィンレスキューのためのオリゴマー化合物
WO2020154693A1 (en) Nrl expression reducing oligonucleotides, compositions containing the same, and methods of their use
WO2025140551A1 (en) COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS
WO2026080897A1 (en) Antisense oligonucleotides for the treatment of chronic pain
TW202508606A (zh) 修飾的核苷類似物及其用途與含核苷酸類似物的雙股寡核苷酸及其用途
US20230212572A1 (en) Guanosine Analogues for Use in Therapeutics Polynucleotides
WO2025043202A1 (en) Compounds and methods for reducing atn1 expression